Taken together, the fact that several gene promoters were specifically bound by PA200 (ChIP‐seq data) and this binding was validated by mRNA expression levels of these genes demonstrated that this cohort of validated promoters was bona fide targets of PA200 in human neuroblastoma cells. This evidence concerns the gene PSME4 and neuroblastoma.